Effect of intracellular uptake of nanoparticle-encapsulated trehalose on the hemocompatibility of allogeneic valves in the VS83 vitrification protocol.
Balamurugan Vasudevan, Qing Chang, Bin Wang, Siyang Huang, Yulong Sui, Wenjie Zhu, Qing Fan, Yisheng Song
{"title":"Effect of intracellular uptake of nanoparticle-encapsulated trehalose on the hemocompatibility of allogeneic valves in the VS83 vitrification protocol.","authors":"Balamurugan Vasudevan, Qing Chang, Bin Wang, Siyang Huang, Yulong Sui, Wenjie Zhu, Qing Fan, Yisheng Song","doi":"10.1177/1849543520983173","DOIUrl":null,"url":null,"abstract":"<p><p>Trehalose is a disaccharide molecule consisting of two molecules of glucose. Industrially, trehalose is derived from corn starch and utilized as a drug. This study aims to examine whether the integration of nanoparticle-encapsulated trehalose to the Ice-Free Cryopreservation (IFC) method for preserving heart valves has better cell viability, benefits to protect the extracellular matrix (ECM), and reduce immune response after storage. For the experiment to be carried out, we obtained materials, and the procedures were carried out in the following manner. The initial step was the preparation of hydroxyapatite nanoparticles, followed by precipitation to acquire Apatite colloidal suspensions. Animals were obtained, and their tissue isolation and grouping were done ethically. All samples were then divided into four groups, Control group, Conventional Frozen Cryopreservation (CFC) group, IFC group, and IFC + T (IFC with the addition of 0.2 M nanoparticle-encapsulated Trehalose) group. Histological analysis was carried out via H&E staining, ECM components were stained with Modified Weigert staining, and the Gomori Ammonia method was used to stain reticular fibers. Alamar Blue assay was utilized to assess cell viability. Hemocompatibility was evaluated, and samples were processed for immunohistochemistry (TNFα and IL-10). Hemocompatibility was quantified using Terminal Complement Complex (TCC) and Neutrophil elastase (NE) as an indicator. The results of the H&E staining revealed less formation of extracellular ice crystals and intracellular vacuoles in the IFC + T group compared with all other groups. The CFC group's cell viability showed better viability than the IFC group, but the highest viability was exhibited in the IFC + T group (70.96 ± 2.53, P < 0.0001, n = 6). In immunohistochemistry, TNFα levels were lowest in both IFC and IFC + T group, and IL-10 expression had significantly reduced in IFC and IFC + T group. The results suggested that the nanoparticle encapsulated trehalose did not show significant hemocompatibility issues on the cryopreserved heart valves.</p>","PeriodicalId":56366,"journal":{"name":"Nanobiomedicine","volume":"7 ","pages":"1849543520983173"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/e9/10.1177_1849543520983173.PMC7780325.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanobiomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1849543520983173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}
引用次数: 0
Abstract
Trehalose is a disaccharide molecule consisting of two molecules of glucose. Industrially, trehalose is derived from corn starch and utilized as a drug. This study aims to examine whether the integration of nanoparticle-encapsulated trehalose to the Ice-Free Cryopreservation (IFC) method for preserving heart valves has better cell viability, benefits to protect the extracellular matrix (ECM), and reduce immune response after storage. For the experiment to be carried out, we obtained materials, and the procedures were carried out in the following manner. The initial step was the preparation of hydroxyapatite nanoparticles, followed by precipitation to acquire Apatite colloidal suspensions. Animals were obtained, and their tissue isolation and grouping were done ethically. All samples were then divided into four groups, Control group, Conventional Frozen Cryopreservation (CFC) group, IFC group, and IFC + T (IFC with the addition of 0.2 M nanoparticle-encapsulated Trehalose) group. Histological analysis was carried out via H&E staining, ECM components were stained with Modified Weigert staining, and the Gomori Ammonia method was used to stain reticular fibers. Alamar Blue assay was utilized to assess cell viability. Hemocompatibility was evaluated, and samples were processed for immunohistochemistry (TNFα and IL-10). Hemocompatibility was quantified using Terminal Complement Complex (TCC) and Neutrophil elastase (NE) as an indicator. The results of the H&E staining revealed less formation of extracellular ice crystals and intracellular vacuoles in the IFC + T group compared with all other groups. The CFC group's cell viability showed better viability than the IFC group, but the highest viability was exhibited in the IFC + T group (70.96 ± 2.53, P < 0.0001, n = 6). In immunohistochemistry, TNFα levels were lowest in both IFC and IFC + T group, and IL-10 expression had significantly reduced in IFC and IFC + T group. The results suggested that the nanoparticle encapsulated trehalose did not show significant hemocompatibility issues on the cryopreserved heart valves.
NanobiomedicineBiochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.80
自引率
0.00%
发文量
1
审稿时长
14 weeks
期刊介绍:
Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered. All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles. Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to: Nanoscale-structured biomaterials, Nanoscale bio-devices, Nanoscale imaging, Nanoscale drug delivery, Nanobiotechnology, Nanorobotics, Nanotoxicology, Nanoparticles, Nanocarriers, Nanofluidics, Nanosensors (nanowires, nanophotonics), Nanosurgery (dermatology, gastroenterology, ophthalmology, etc), Nanocarriers commercialization of nanobiomedical technologies, Market trends in the nanobiomedicine space, Ethics and regulatory aspects of nanobiomedicine approval, New perspectives of nanobiomedicine in clinical diagnostics, BioMEMS, Nano-coatings, Plasmonics, Nanoscale visualization.